Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
What goes down must come up.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
And the move will shake up the orthopaedic robotics scene.
It takes more than a pandemic to stop medical device companies merging.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.